Back to search

Article

Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignancies

2026-07-20

Abstract excerpt

<h4>ABSTRACT</h4> Impaired cellular differentiation is a defining characteristic of myeloid malignancies and remains a major therapeutic challenge. The BRG1/Brahma-associated factor (BAF) chromatin remodeling complex, through the ATPases SMARCA4 and SMARCA2, maintains the stemness of leukemic blasts and thus represents a promising target for novel differentiation-based therapies. In a phase 1 study in advanced my...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fe0a7a28-ce40-5a76-8519-ac445af5766c
DOI
10.64898/2026.07.17.26358055
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignanciesDOI 10.64898/2026.07.17.26358055
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitorSemantic proximity
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorSemantic proximity
Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell linesSemantic proximity
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaSemantic proximity
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLSemantic proximity
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.Semantic proximity
Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic ParadigmsSemantic proximity
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.Semantic proximity
Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell RemodelingSemantic proximity
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLSemantic proximity
Select a neighboring publication to make it the new centre.